Home
Home

Qnexa

Obesity And The FDA: Why Qnexa Is Generating Buzz

Obesity And The FDA: Why Qnexa Is Generating Buzz
Seeking Alpha

A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee

A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee
Elsevier Business

Arena Pharmaceuticals' Lorcaserin Will Be A Blockbuster Drug

Arena Pharmaceuticals' Lorcaserin Will Be A Blockbuster Drug
Seeking Alpha

Obesity Epidemic Prompting Vivus Takeover Talk With 68% Windfall: Real M&A

Obesity Epidemic Prompting Vivus Takeover Talk With 68% Windfall: Real M&A
Bloomberg

Vivus's Qnexa And Its Potential Value

Vivus's Qnexa And Its Potential Value
Seeking Alpha

Vivus Drug Won't Solve U.S. Weight Woes, Says Author (video)

Vivus Drug Won't Solve U.S. Weight Woes, Says Author (video)
The Street

How Qnexa's Positive Panel Review Generated Alpha For Short Sellers

How Qnexa's Positive Panel Review Generated Alpha For Short Sellers
Seeking Alpha

Vivus rockets 99% on FDA nod

Vivus rockets 99% on FDA nod
Marketwatch

FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa

FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa
Washington Post, DC

Vivus: FDA Panel Live Blog

Vivus: FDA Panel Live Blog
TheStreet.com